Evidence map›Paper›PMID 33505137›Full record

ArticleIndian journal of clinical biochemistry : IJCB2021

Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer.

Sumanpreet Kaur, Rajasri Bhattacharyya, Dibyajyoti Banerjee, Jaya Shukla

Open access · greenAbstract read
In one paragraph

Article in Indian journal of clinical biochemistry : IJCB, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sumanpreet KaurDepartment of Experimental Medicine and Biotechnology, PGIMER, Chandigarh, 160012 India.
Rajasri BhattacharyyaDepartment of Experimental Medicine and Biotechnology, PGIMER, Chandigarh, 160012 India.
Dibyajyoti BanerjeeDepartment of Experimental Medicine and Biotechnology, PGIMER, Chandigarh, 160012 India.
Jaya ShuklaDepartment of Nuclear Medicine, PGIMER, Chandigarh, 160012 India.
Post Graduate Institute of Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Synergism in action of tucatinib and trastumab is reported in breast cancer management. However, its molecular basis is yet to be determined. In this context we attempted to provide an explanation at the molecular level by performing in silico experimentation and coupling its result with already available published observations. Our study will provide basis for planning further experimental study for unravelling the truth.

Indexed as

Breast cancerSynergismTrastumabTucatinib

Identifiers

PMID33505137
PMCPMC7817741
OpenAlexW2994343109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.